Skip to content

Medications for RSV: Nursing Pharmacology

Notes

Notes

MEDICATIONS for RSV
DRUG NAME
ribavirin
palivizumab (Synagis)
CLASS
Antiviral
Monoclonal antibody
MECHANISM of ACTION
  • Ribavirin is a purine nucleoside analogue whose phosphorylated form resembles the natural nucleotides present in the cells. 
  • It gets inserted into the growing nucleic acid chain by the RSV RNA-dependent RNA polymerase and inhibits elongation
  • Inhibits the enzyme inosine-5′-phosphate dehydrogenase, and prevents synthesis of guanine nucleotides
  • Inhibits RSV nucleic acid synthesis
  • Monoclonal antibody against the RSV fusion protein, which helps the virus fuse to the host cell membrane and enter it; also facilitates the fusion between infected cell membranes, resulting in syncytium formation
  • Neutralizes the fusion protein and prevents RSV from infecting the host cells and syncytium formation
INDICATIONS
  • Severe cases of bronchiolitis
  • Immunocompromised children with RSV
  • HCV and HEV infection
  • Prevention in infants at high risk for RSV including prematurely-born infants, those with chronic lung disease, or congenital heart disease
ROUTE(S) of ADMINISTRATION
PO, Inhalation
IM
SIDE EFFECTS
  • Headache, fatigue, insomnia, depression
  • Rash, itching
  • Cough
  • Nausea, abdominal pain 
  • Hyperuricemia
  • Boxed warnings: hemolytic anemia, teratogenic
  • Injection site reactions
  • Fever, chills, myalgia
  • Nausea, vomiting
  • Rash, itching, angioedema, anaphylaxis
  • Thrombocytopenia

CONTRAINDICATIONS & CAUTIONS
  • Pregnancy
  • Hemoglobinopathies (e.g., thalassemia, sickle-cell anemia) 
  • Autoimmune hepatitis
  • Severe renal disease

Drug interactions:
  • Interferons, nucleoside reverse transcriptase inhibitors: Ribavirin toxicity
  • Decreased effects of vitamin K antagonists, as well as live attenuated influenza vaccines

  • Thrombocytopenia and other bleeding disorders

Drug interactions:
  • Thrombolytic, antiplatelet, and anticoagulant medications: Increased risk of bleeding
NURSING CONSIDERATIONS for
MEDICATIONS for RSV
ASSESSMENT AND MONITORING
Assessment and monitoring: palivizumab
Assessment
  • Medical history, risk factors for RSV disease
  • Ask parents / caregivers about current signs of infection: irritability, poor feeding
  • Weight
  • Vital signs
  • Lung sounds

Administration
  • Confirm the correct calculation of the medication to be administered in mg/kg
  • Ensure that emergency equipment is available
  • Select the correct needle length and injection site
    • Vastus lateralis muscle; do not massage after the injection
  • Age-appropriate steps to reduce pain

Monitoring
  • Monitor the child for 15 minutes for signs of hypersensitivity reaction
  • Desired therapeutic effect: absence of RSV infection
CLIENT EDUCATION
  • Basics of RSV
  • Purpose of medication: decrease risk of contracting RSV
  • Administered by injection every month for five months, during RSV season
  • Ways to reduce risk of infection
    • Maintaining a smoke free environment, encouraging breastfeeding, keeping their child away from crowds and others who are sick, practicing good hand hygiene
  • Side effects
  • Injection site reactions
    • Apply cool compress 
  • Fever
    • Administer prescribed acetaminophen
  • Seek immediate medical care
    • Abnormally fast or slow breathing, wheezing, swelling of the face or throat, difficulty swallowing, unusual bruising, unusual rash, other concerning symptoms
Transcript

Respiratory syncytial virus, or RSV for short, is an enveloped RNA virus that causes the cells lining the respiratory tract to merge, forming a large multinucleated cell called syncytia. RSV commonly affects the lower respiratory tract of young children, causing bronchiolitis.

Initially, bronchiolitis often resembles the common cold, but in some cases, it can also progress to atelectasis, or airway collapse, which causes severe symptoms such as wheezing, dyspnea, and even apnea in young infants.

There are two main classes of medication used in the treatment of RSV infection; these include monoclonal antibodies like palivizumab, and antiviral medications like ribavirin.

Starting with palivizumab, this medication is administered via intramuscular injection and is given for prevention, during the winter months, to infants at high risk for RSV, including prematurely-born infants, and to those with chronic lung disease or congenital heart disease.

Now, palivizumab is a monoclonal antibody that targets the fusion protein on the surface of RSV. The fusion protein helps the virus fuse to the host cell membrane and enter it, also facilitates the fusion between infected cell membranes, resulting in syncytium formation.

So by neutralizing the fusion protein, palivizumab prevents RSV from infecting the host cells and forming syncytia.

Common side effects of palivizumab include injection site reactions like pain, redness, and swelling. Some clients may also present with fever, chills, and myalgia.

Other side effects include nausea, vomiting, dyspnea, and hypersensitivity reactions like skin rashes, pruritus, angioedema, and even anaphylaxis.

Additionally, palivizumab can also cause thrombocytopenia, which can result in easy bruising or bleeding.

Now, palivizumab should be used with caution in children with thrombocytopenia and other bleeding disorders due to increased risk of bleeding.

Additionally, palivizumab should be used with caution when combined with thrombolytic, antiplatelet, and anticoagulant medications, as it can increase the risk of bleeding.

Now let’s switch gears and look at ribavirin, which is usually given orally or through inhalation to reduce the viral load in severe cases of bronchiolitis and to children who are immunocompromised and have an RSV infection.

In addition, ribavirin can be used to treat clients with chronic hepatitis C or E infection. Ribavirin is a purine nucleoside analog, which once administered, goes inside the infected cells, and gets picked up by the viral RNA-dependent RNA polymerase when trying to synthesize new nucleic acid.

As a result, these fake nucleotides are incorporated into the growing RNA, so no additional nucleotides can be added. Ultimately, this brings viral replication to a halt.

Additionally, ribavirin also inhibits the enzyme inosine-5′-phosphate dehydrogenase, which is essential to synthesize guanine nucleotides. As a result, the lack of guanine nucleotides further impairs viral replication.

Now, the most common side effects of ribavirin include headache, fatigue, abdominal pain, and nausea.

Some clients may also experience insomnia, depression, or develop a skin rash, pruritus, and cough.

In addition, ribavirin can cause hyperuricemia, or increased uric acid levels, since it's not metabolized by cells that lack a nucleus like the red blood cells and accumulates within them. Finally, ribavirin has boxed warnings for causing hemolytic anemia and teratogenic effects.

Ribavirin is contraindicated during pregnancy, in males whose female partners are pregnant, as well as in clients with hemoglobinopathies like thalassemia and sickle-cell anemia.

Ribavirin should be used with caution in clients with autoimmune hepatitis and severe renal disease.

Sources
  1. "Focus on Nursing Pharmacology" LWW (2019)
  2. "Pharmacology" Elsevier Health Sciences (2014)
  3. "Mosby's 2021 Nursing Drug Reference" Mosby (2020)
  4. "Saunders Comprehensive Review for the NCLEX-RN Examination" Saunders (2016)
  5. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  6. "First Aid for the USMLE Step 1 2018, 28th Edition" McGraw-Hill Education / Medical (2017)
  7. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  8. "Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion" Journal of Virology (2010)
  9. "Synagis® (palivizumab) injection for intramuscular use"  (2012)
  10. "COPEGUS (ribavirin, USP) TABLETS "  (2002)
  11. "Lehne's Pharmacology for Nursing Care" Elsevier Health Sciences (2014)
  12. "Palivizumab Injection" MedlinePlus (2016)
  13. "Palivizumab for at-risk patients"  (2021)